V-Wave will now operate within the Johnson & Johnson MedTech division. Credit: Michael Vi/Shutterstock.

Johnson & Johnson (J&J) has announced the completion of its acquisition of V-Wave, a company specialising in the development of heart failure treatments.

V-Wave will now function under the Johnson & Johnson MedTech division.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The acquisition will add the company’s new and minimally invasive Ventura interatrial shunt to the MedTech portfolio.

The strategic move bolsters Johnson & Johnson MedTech’s presence in the cardiovascular market and addresses the critical need for advanced heart failure therapies.

In August 2024, J&J first entered an agreement to acquire the heart failure implant company in a deal that could reach $1.7bn.

The acquisition is expected to enhance J&J’s growth in potential markets and add to its comprehensive medical technology portfolio, which includes solutions for coronary and peripheral artery diseases, heart recovery and atrial fibrillation.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

It also enables Johnson & Johnson MedTech to deepen its engagement with structural interventional cardiologists and specialists in heart failure treatment.

Johnson & Johnson MedTech worldwide chairman and executive vice-president Tim Schmid stated: “We’re excited to officially welcome V-Wave to Johnson & Johnson MedTech. V-Wave’s novel implantable device, the Ventura interatrial shunt, offers tremendous promise for patients experiencing heart failure with reduced ejection fraction.

“This technology has the potential to be the first device of its kind to market. We look forward to working with the talented V-Wave team to bring this transformative innovation to patients.”

J&J has disclosed that this transaction is expected to dilute adjusted earnings per share (EPS) by $0.24 in 2024 and by $0.06 in 2025.

The company plans to provide an updated financial outlook for the full year 2024 during its third-quarter earnings report on 15 October 2024.

Medical Device Network Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Medical Device Network Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving medical devices advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now